Pacific Biosciences Of California (PACB) Total Non-Current Liabilities (2016 - 2026)
Pacific Biosciences Of California has reported Total Non-Current Liabilities over the past 13 years, most recently at $778.7 million for Q4 2025.
- For Q4 2025, Total Non-Current Liabilities rose 3.38% year-over-year to $778.7 million; the TTM value through Dec 2025 reached $778.7 million, up 3.38%, while the annual FY2025 figure was $778.7 million, 3.38% up from the prior year.
- Total Non-Current Liabilities for Q4 2025 was $778.7 million at Pacific Biosciences Of California, up from $767.1 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $1.2 billion in Q4 2021 and troughed at -$200.0 million in Q3 2021.
- A 5-year average of $942.8 million and a median of $1.0 billion in 2023 define the central range for Total Non-Current Liabilities.
- Biggest five-year swings in Total Non-Current Liabilities: surged 1459.76% in 2021 and later dropped 27.84% in 2024.
- Year by year, Total Non-Current Liabilities stood at $1.2 billion in 2021, then fell by 0.79% to $1.2 billion in 2022, then dropped by 13.21% to $1.0 billion in 2023, then dropped by 27.84% to $753.3 million in 2024, then grew by 3.38% to $778.7 million in 2025.
- Business Quant data shows Total Non-Current Liabilities for PACB at $778.7 million in Q4 2025, $767.1 million in Q3 2025, and $764.0 million in Q2 2025.